Company intelligence / Profile preview
Onconetix, Inc.
Cincinnati, Ohio, United Statesonconetix.com ↗
- Ownership
- Public · ONCO
- Employees
- ~12
- Development stage
- Other
01
Overview
Onconetix, Inc. is a commercial-stage biotechnology company specializing in proprietary therapeutics and diagnostics for oncology and men’s health. Its lead products are Entadfi®, an FDA-approved oral therapy for BPH that combines finasteride and tadalafil, and Proclarix®, a diagnostic blood test to aid prostate cancer diagnosis in men with indeterminate PSA results. The company was formerly known as Blue Water Biotech before rebranding to Onconetix after acquiring Proteomedix in late 2023.
- Therapeutic areas
- Men's HealthOncology
- Modalities
- Small molecules (Entadfi® combines finasteride and tadalafil)In vitro diagnostics (Proclarix® protein-based blood test)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Financials
- Market cap
- $2M
- Total revenue
- $815.4K
- Enterprise value
- $-3.8M
Beyond the preview
Go deeper on Onconetix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onconetix, Inc..